GENE ONLINE|News &
Opinion
Blog

2021-12-22| M&A

Sanofi Bets $1 Billion on Preclinical Next-gen Immunotherapies

by Joy Lin
Share To
Ever since Amgen’s Blincyto (blinatumomab) won the first FDA approval for a T-cell engager in 2014, companies have been rushing to enter the space. Sanofi is paying $1 billion upfront to acquire a US-based immuno-oncology company developing drugs that activate in the tumor microenvironment.

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)
2024-05-10
Biotech in Beauty: Engineered Skin Bacteria Designed To Treat Acne
2024-05-10
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
Advancing Health: ASGCT’s Clinical Trials Spotlight on Cell Therapy and Cell-Based Gene Therapy
2024-05-09
Infinitopes’ Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
2024-05-09
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top